Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Alex A. Adjei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8039-6556; OpenAlex author ID A5113962365. Sources: OpenAlex.

Their work

Papers
6 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 6

  1. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16101861↗
  2. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Co-author DOI 10.1016/j.pan.2020.06.015↗
  3. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Last author DOI 10.1097/coc.0000000000000492↗
  4. Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models. Co-author DOI 10.1038/bjc.2013.754↗
  5. Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Co-author DOI 10.1097/cad.0000000000000009↗
  6. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with soli… Co-author DOI 10.1158/1078-0432.ccr-11-2813↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wen Wee Ma · 3 shared papers, 2012–2024 · strength 0.27
  2. Ryan Michael Carr · 2 shared papers, 2020–2024 · strength 0.25
  3. Tanios Bekaii‐Saab · 2 shared papers, 2020–2024 · strength 0.25
  4. Aaron Scott Mansfield · 2 shared papers, 2013–2024 · strength 0.21
  5. Alexander Revzin · 1 shared paper, 2024 · strength 0.17
  6. Thorvardur Ragnar Halfdanarson · 1 shared paper, 2024 · strength 0.17
  7. Sani Haider Kizilbash · 1 shared paper, 2024 · strength 0.17
  8. Daniel H. Ahn · 1 shared paper, 2024 · strength 0.17
  9. Aakash P. Desai · 1 shared paper, 2024 · strength 0.17
  10. Daheui Choi · 1 shared paper, 2024 · strength 0.17
  11. Hani M. Babiker · 1 shared paper, 2024 · strength 0.17
  12. Steven R. Alberts · 1 shared paper, 2024 · strength 0.17
  13. Robert R. McWilliams · 1 shared paper, 2024 · strength 0.17
  14. Amit Mahipal · 1 shared paper, 2024 · strength 0.17
  15. Charles Erlichman · 2 shared papers, 2013–2020 · strength 0.13
  16. Robert M. Straubinger · 2 shared papers, 2014–2019 · strength 0.13
  17. Mitesh J. Borad · 1 shared paper, 2020 · strength 0.09
  18. Thomas C. Smyrk · 1 shared paper, 2020 · strength 0.09
  19. Angela L. McCleary‐Wheeler · 1 shared paper, 2020 · strength 0.09
  20. Rondell Patrell Graham · 1 shared paper, 2020 · strength 0.09
  21. George Kim · 1 shared paper, 2020 · strength 0.09
  22. Martín E. Fernández-Zapico · 1 shared paper, 2020 · strength 0.09
  23. Hao Xie · 1 shared paper, 2019 · strength 0.08
  24. Renuka V. Iyer · 1 shared paper, 2019 · strength 0.08
  25. W W Ma · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.